Aloi M, et al. - In this retrospective study, the researchers assessed the effectiveness and safety of adalimumab (ADA) in children with ulcerative colitis (UC) previously treated with infliximab (IFX). Study participants were children with UC from a national registry who received ADA therapy. The rate of corticosteroid-free remission at week 52 was the primary endpoint. The rate of sustained clinical remission, primary nonresponse, and loss of response at weeks 12, 30, and 52 and rate of mucosal healing and side effects at week 52 were the secondary outcomes. Results of this study suggested that ADA seems to be effective in children with UC, allowing to recover a significant percentage of patients intolerant or not-responding to IFX. In addition, the safety profile was good.